2025 was a transformative year for cardiovascular medicine, marked by groundbreaking discoveries and paradigm shifts in treatment and risk assessment. The field witnessed a significant shift in interventional cardiology, with research and clinical updates challenging long-held assumptions and paving the way for innovative treatments. One of the most notable developments was the reevaluation of aspirin's role in cardiovascular health. Numerous studies, including those reported by The Medical Republic, questioned the routine use of aspirin, highlighting increased risks that outweigh potential benefits. Researchers concluded that aspirin's long-standing recommendation was based on outdated evidence, and superior antiplatelet therapies like clopidogrel may soon replace it as the preferred choice. A clinical trial even had to be halted early due to excess deaths, prompting a reevaluation of prescribing practices. This finding underscores the importance of staying updated with the latest research to ensure patient safety and effectiveness of treatment. Another significant development was the push for single-pill combinations (SPCs) and fixed-dose combinations (FDCs) as first-line hypertension treatment. There were urgent calls for changes to the Pharmaceutical Benefits Scheme (PBS) to facilitate this shift, but as of the article's publication in August, these restrictions remain in place, and updates to the Australian Hypertension Guidelines have not been released. Australian researchers also made a breakthrough in CRISPR gene-editing technology, conducting the first in-human trial to manage cholesterol. The trial demonstrated significant reductions in cholesterol and triglycerides with a single injection of editing tools, marking a potential breakthrough for treating mixed lipid disorders. In the realm of lipids, the European Society of Cardiology and the European Atherosclerosis Society released new international recommendations for dyslipidaemia management. These guidelines proposed a more aggressive approach to lipid-lowering regimens, moving away from the traditional 'low and slow' tactic. The guidelines also emphasized the importance of utilizing Lp(a) testing for heart disease prevention, a long-overlooked risk factor that could prevent numerous cardiovascular events. The annual American Heart Association scientific sessions showcased multiple studies on PCSK9 inhibitors in cholesterol management, including a large trial of an oral version of the injectable medication. One study found that pairing PCSK9 inhibitors with statins provided additional protection, significantly reducing the risk of cardiovascular death, heart attack, or ischemic stroke. Cardiologists from Italy, Germany, and the US, in a viewpoint published in the European Heart Journal, reflected on the pivotal role of randomized clinical trials in reshaping interventional cardiology practices, procedural strategies, and long-term expectations for percutaneous therapies. These trials refined antiplatelet management after PCI, clarified the optimal timing of multivessel revascularization, and extended our understanding of transcatheter aortic valve implantation (TAVI) durability in low-risk patients. These advancements in cardiovascular medicine not only highlight the field's rapid progress but also emphasize the importance of staying updated with the latest research to ensure patient safety and effectiveness of treatment.
